Chief Corporate Development Officer
Andrew joined Tilray in March 2019 from Goldman Sachs, where he was a Managing Director and most recently served as Head of Canadian Diversified Investment Banking, which included coverage of the Canadian cannabis industry. Previously, he was a member of Goldman Sachs’ Global Healthcare Investment Banking Group in New York, where he advised on more than $200 billion in announced M&A and financing transactions, with a focus on the biopharmaceutical sector.
Andrew leads Tilray’s corporate development function, including the team that is responsible for M&A and corporate investments.
Simon Fraser University
York University: JD/MBA